← Issue №15/ week of Oct 11, 2026/Colorectal

Commonly prescribed drugs as risk factors for Clostridioides difficile infections: a Swedish population-based case-control study.

From GI Signals issue №15: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal retrospective · n=42,921 · Oct 7, 2026 · Gut · IF 24.6

Commonly prescribed drugs as risk factors for Clostridioides difficile infections: a Swedish population-based case-control study.

New evidenceepidemiologymicrobiome
Clinical takeawayConsider avoiding lincosamides and penicillin combinations in high-risk patients when alternatives exist, and weigh CDI risk when prescribing PPIs, antidiarrheals, corticosteroids, and other non-antibiotic drugs. Lipid-modifiers and aspirin may offer protective effects, but risks and benefits should be carefully evaluated in individual patients.
What it foundLincosamides had the highest CDI risk (aOR=31.4), followed by penicillin combinations (aOR=19.8), while lipid-modifiers and aspirin reduced CDI risk (aOR=0.8 each).
ContextConfirms PPIs as a CDI risk factor and identifies new associations with non-antibiotic drugs, refining antimicrobial stewardship strategies. Findings are based on a Swedish population-based case-control study from 2006 to 2019.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Boven A … Brusselaers N · Gut · IF 24.6 · PubMed ↗Permalink
← Read the whole of issue №15 Every paper GI Signals surfaces gets a page like this one. All issues